Marcela V. Maus

6 ta ish

Massachusetts General Hospital

1. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

   Noopur Raje, Jesús G. Berdeja, Yi Lin +20

   MaqolaOAOchiq kirish20195 iqtibos

   ABIABI:AkademIndex/2026.other.082848

2. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

   Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.020482

3. Engineering and Design of Chimeric Antigen Receptors

   Sònia Guedan, Hugo Calderón, Avery D. Posey +1

   Sharh maqola20184 iqtibos

   ABIABI:AkademIndex/2026.other.340858

4. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

   Bryan D. Choi, Xiaoling Yu, Ana P. Castaño +14

   MaqolaOAOchiq kirish20192 iqtibos

   ABIABI:AkademIndex/2026.other.020532

5. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

   Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.082777

6. Gene editing for immune cell therapies

   Stefanie R. Bailey, Marcela V. Maus

   Sharh maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.296851